PATENT CLAIM ANALYSIS

Application Number: 15762949
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "026000"]

Abstract:
The present invention is related to a combination for treating an EV71 infection, which comprises two or more compounds at each's non-effective level and provides an unexpected synergistic activity against EV71 replication, wherein the compound is selected from the group consisting of auranofin, ouabain, emetine, niclosamide, and S-(+)-fluoxetine.

Claim (Index 32):
The combination of  claim 22 , wherein the non-effective level of S-(+)-fluoxetine is below 20 mg per day for a human subject.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 90.0
- Lexical Diversity: 1.2
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13983722', '14384075', '15307926', '14935227', '15796403']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7609406936536638
- 35 USC 102 Novelty (BERT): 0.5121115746009341
- Combined Prediction Score: 0.7360577817483909
- Mean Citation Score: 220.185332
- Max Citation Score: 241.55122000000003
- Similarity Product: 146.18796277376654

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test